Drugs / CD20/CD22/CD10-CART
CD20/CD22/CD10-CART
also known as
CD22/CD19 CAR-T cell immunotherapy · CD22/CD19 Dual-Target CAR-T Cells · Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells · CAR-T cells targeting CD19 and CD22 · CD22 · CD22/CD19 CAR-T cell
Cell therapy targets CD19, CD22
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03407859 | Jan 2016 → Dec 2024 | therapy-related myeloid neoplasm | Zhujiang Hospital | Unknown | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT05388695 | Apr 2022 → Mar 2027 expected | B-cell neoplasm | Hebei Senlang Biotechnology Inc., Ltd. | Recruiting | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07575919 | Jan → Dec 2026 expected | B-cell acute lymphoblastic leukemia | Liping Dou | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07575971 | Jan → Dec 2026 expected | B-cell acute lymphoblastic leukemia | Liping Dou | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04740203 | Jan 2021 → Jan 2024 | B-cell adult acute lymphocytic leukemia | Zhejiang University | Unknown | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT07587840 | Jan 2026 → Jan 2027 expected | lymphoma | Liping Dou | Recruiting | No outcome recorded |
| Phase 2 | NCT06985498 | Jun 2025 → Jun 2029 | acute lymphoblastic leukemia | The First Affiliated Hospital of Soochow University | Suspended | No outcome recorded |
| Phase 2 | NCT07094477 | Apr 2025 → Mar 2027 expected | lymphoma | Daihong Liu | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05470777 | Jan 2020 → Jul 2026 overdue | B-cell acute lymphoblastic leukemia | The First Affiliated Hospital of Soochow University | Active not recruiting | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD20/CD22/CD10-CART | “Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment in Relapsed/Refractory B-ALL” NCT03407859 ↗ |
| Known as | Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05388695 ↗ |
| Known as | CAR-T cells targeting CD19 and CD22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740203 ↗ |
| Known as | CD22 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470777 ↗ |
| Known as | CD22/CD19 CAR-T cell | “Immunotherapies includes CD19-directed CD3 T-cell engager, inotuzumab ozogamicin (INO) and CD22/CD19 CAR-T cell.” NCT06985498 ↗ |
| Known as | CD22/CD19 CAR-T cell immunotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07094477 ↗ |
| Known as | CD22/CD19 Dual-Target CAR-T Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07575971 ↗ |
| Action | Deplete | “will kill and eliminate CD19 negative B-ALL cells” NCT03407859 ↗ |
| Modality | Cell therapy | “Chimeric Antigen Receptor-transduced T cell (CAR-T) therapy” NCT03407859 ↗ |
| Route | Intravenous | “Each subject receives sequential CD19 and CD22 CAR-T cells by intravenous infusion” NCT04740203 ↗ |
| Target | CD19 | “Single or sequential injection of CD19, CD20 and CD22 CAR T cells.” NCT05388695 ↗ |
| Target | CD22 | “Single or sequential injection of CD19, CD20 and CD22 CAR T cells.” NCT05388695 ↗ |